Seeking out predictive biomarkers to FGFR inhibitors in molecularly-selected metastatic breast cancer
Over recent years, the development of CDK4/6 [...]
VHIO’s Enriqueta Felip takes up the reins as SEOM President (2021-2023)
Officially announced at the Spanish Society of [...]
VHIO investigators co-author new ESMO Clinical Practice Guideline with evidence-based recommendations for the treatment of metastatic breast cancer
Marking this October’s Breast Cancer Awareness Month, [...]
VHIO-led research reveals a driver of adaptive resistance to therapies targeting KIT mutations in GIST
Mutations in the KIT proto-oncogene and dysregulated [...]
RAD51 as a biomarker of homologous recombination deficiency & predictor of clinical outcomes in patients with triple-negative breast cancer
Developed in-house by VHIO’s Experimental Therapeutics Group, [...]
Posttranslational modification as a regulator of protein function: a review of latest insights & the signposting of next directions
Recently published as an open access Mini [...]
Elena Garralda’s ESMO On target column: considering the concordance of treatment recommendations between central consensus & MTBs
In her latest ESMO perspectives On target [...]
Now open: VHIO’s first institutional call for applications for pre-doctoral research fellowships
Barcelona, September 30, 2021. The Vall d'Hebron [...]
Ivosidenib as a promising new contender against advanced cholangiocarcinoma
Cholangiocarcinoma (CCA) is a highly aggressive, heterogeneous [...]
ecancer catches up with VHIO’s Enriqueta Felip & Cristina Saura on new therapeutic avenues against NSCLC and breast cancer, respectively
Reflective of the relevance of just some [...]